Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Tonics Pharmaceuticals' second quarter 2026 Financial Results and Business Update conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question and answer session. As a reminder, this call is being recorded. I would like to turn the call over to Deborah Elson, Head of Investor Relations at Tonics Pharmaceuticals. Please go ahead. Thank you, Operator, and good morning, everyone. We appreciate you joining us today to discuss Tonics Pharmaceuticals' second quarter 2026 financial results and operational highlights. Before we begin, I would like to remind everyone of the disclaimers on slide two that any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks are described more fully in our filing, the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31st, 2025 and our subsequent periodic reports. Tonics undertakes no obligation to update or revise any forward-looking statements except as required by law. Joining me on today's call are Dr. Seth Lederman, Chief Executive Officer, Thomas Englese, Executive Vice President of Commercial Operations, and Bradley Saenger, Chief Financial Officer. With that, I will turn the call over to Seth. Seth? Thank you, Deborah, and good morning, everyone. We're pleased to welcome you to Tonics' earnings call. Today we're reporting second quarter financial results and operational hi...